home / stock / gnpx / gnpx short
Short Information | Genprex Inc. (NASDAQ:GNPX)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 161,655 |
Total Actual Volume | 862,725 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 8,083 |
Average Short Percentage | 19.30% |
Is there a GNPX Short Squeeze or Breakout about to happen?
See the GNPX Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-22-2024 | $2.29 | $2.163 | $2.38 | $2.12 | 19,431 | 3,087 | 15.89% |
04-19-2024 | $2.23 | $2.13 | $2.5 | $2.09 | 38,192 | 8,933 | 23.39% |
04-18-2024 | $2.27 | $2.2194 | $2.27 | $2.18 | 17,493 | 4,176 | 23.87% |
04-17-2024 | $2.35 | $2.21 | $2.542 | $2.2 | 20,749 | 2,943 | 14.18% |
04-16-2024 | $2.39 | $2.3 | $2.45 | $2.27 | 20,368 | 1,754 | 8.61% |
04-15-2024 | $2.77 | $2.35 | $2.77 | $2.35 | 32,896 | 10,140 | 30.82% |
04-12-2024 | $2.78 | $2.68 | $2.8699 | $2.65 | 20,689 | 3,984 | 19.26% |
04-11-2024 | $2.81 | $2.78 | $2.9122 | $2.74 | 16,842 | 2,717 | 16.13% |
04-10-2024 | $3.03 | $2.88 | $3.03 | $2.73 | 49,924 | 11,655 | 23.35% |
04-09-2024 | $3.03 | $3.07 | $3.23 | $2.9101 | 126,928 | 10,851 | 8.55% |
04-08-2024 | $3.106 | $2.96 | $3.24 | $2.94 | 21,454 | 2,148 | 10.01% |
04-05-2024 | $2.99 | $3 | $3.1786 | $2.97 | 17,583 | 5,051 | 28.73% |
04-04-2024 | $3.15 | $2.99 | $3.18 | $2.96 | 44,470 | 10,681 | 24.02% |
04-03-2024 | $2.89 | $3.11 | $3.27 | $2.89 | 97,702 | 34,069 | 34.87% |
04-02-2024 | $2.8 | $2.84 | $3 | $2.7206 | 56,497 | 5,849 | 10.35% |
04-01-2024 | $3 | $2.97 | $3.01 | $2.84 | 47,187 | 9,423 | 19.97% |
03-28-2024 | $2.76 | $2.98 | $3.015 | $2.725 | 30,047 | 9,145 | 30.44% |
03-27-2024 | $2.85 | $2.71 | $2.9 | $2.5 | 50,445 | 10,694 | 21.2% |
03-26-2024 | $3.01 | $2.74 | $3.01 | $2.7 | 57,381 | 8,214 | 14.31% |
03-25-2024 | $3.17 | $3 | $3.27 | $2.9335 | 76,447 | 6,141 | 8.03% |
News, Short Squeeze, Breakout and More Instantly...
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting PR Newswire Compelling Data Validates the Potential...
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Multiple clinical trial sites to be opened under collaboration with large network of community-based oncol...
Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizin...